NDAORALTABLET
Approved
Mar 2024
Lifecycle
Growth
Competitive Pressure
0/100
Clinical Trials
27
Data completeness
5/8 — Partial
VOYDEYA (danicopan) by AstraZeneca is complement factor d inhibitors [moa]. Approved for paroxysmal nocturnal hemoglobinuria. First approved in 2024.
Drug data last refreshed 20h ago
Mechanism of Action
Complement Factor D Inhibitors
Pharmacologic Class:
Complement Factor D Inhibitor
Indications (1)
Clinical Trials (27)
Danicopan PMS in Korea
Started Apr 2026
8 enrolled
Paroxysmal Nocturnal Hemoglobinuria
Assess Long-Term Safety of Danicopan Add-on Therapy in Participants With Paroxysmal Nocturnal Hemoglobinuria: Analysis of IPIG-Registry Data
Started Jan 2026
50 enrolled
Paroxysmal Nocturnal HemoglobinuriaPNH
Long-term Safety of Danicopan: IPIG Registry-based Cohort Study
Started Aug 2025
50 enrolled
Paroxysmal Nocturnal HemoglobinuriaPNH
Study of Danicopan as Add-on Treatment to Ravulizumab or Eculizumab in Pediatric Participants With PNH Who Have Clinically Significant Extravascular Hemolysis
Started Aug 2025
6 enrolled
Paroxysmal Nocturnal HemoglobinuriaPNHExtravascular Hemolysis
A Long-term Safety and Efficacy Study of Danicopan as an Add-on Therapy to Complement Component 5 Inhibitor (C5i) in Participants With PNH
Started Oct 2022
80 enrolled
Paroxysmal Nocturnal Hemoglobinuria
Worked on VOYDEYA at AstraZeneca? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.